Lentivirus Mediated Correction of Artemis-Deficient Severe Combined Immunodeficiency

Divya Punwani,^{1,†} Misako Kawahara,^{1,†} Jason Yu,^{1,†} Ukina Sanford,¹ Sushmita Roy,¹ Kiran Patel,¹ Denise A. Carbonaro,² Andrea D. Karlen,³ Sara Khan,¹ Kenneth Cornetta,⁴ Michael Rothe,⁵ Axel Schambach,⁵ Donald B. Kohn,² Harry L. Malech,⁶ R. Scott McIvor,³ Jennifer M. Puck,^{1,*,†} and Morton J. Cowan^{1,*,†}

¹Department of Pediatrics, University of California School of Medicine and University of California San Francisco Benioff Children's Hospital, San Francisco, San Francisco, California; ²Departments of Microbiology, Immunology and Molecular Genetics and Pediatrics, University of California Los Angeles, Los Angeles, California; ³Department of Genetics, Cell Biology and Development, University of Minnesota, Minneapolis, Minnesota; ⁴Department of Medical and Molecular Genetics, Indiana University, and the Indiana University Viral Production Facility, Indianapolis, Indiana; ⁵Institute for Experimental Hematology, Hannover Medical School, Hannover, Germany; ⁶Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, Division of Intramural Research, National Institutes of Health, Bethesda, Maryland.

[†]These authors contributed equally to this study.

During B and T lymphocyte maturation, V(D)J recombination is initiated by creation of DNA double-strand breaks. Artemis is an exonuclease essential for their subsequent repair by nonhomologous end-joining. Mutations in *DCLRE1C*, the gene encoding Artemis, cause T⁺B⁺NK⁺ severe combined immunodeficiency (ART-SCID) and also confer heightened sensitivity to ionizing radiation and alkylating chemotherapy. Although allogeneic hematopoietic cell transplantation can treat ART-SCID, conditioning regimens are poorly tolerated, leading to early mortality and/or late complications, including short stature, endocrinopathies, and dental aplasia. However, without alkylating chemotherapy as preconditioning, patients usually have graft rejection or limited T cell and no B cell recovery. Thus, addition of normal *DCLRE1C* cDNA to autologous hematopoietic stem cells is an attractive strategy to treat ART-SCID. We designed a self-inactivating lentivirus vector containing human Artemis cDNA under transcriptional regulation of the human endogenous Artemis promoter (AProArt). Fibroblasts from ART-SCID patients transduced with AProArt lentivirus showed correction of radiosensitivity. Mobilized peripheral blood CD34⁺ cells from an ART-SCID patient as well as hematopoietic stem cells from Artemis-deficient mice demonstrated restored T and B cell development following AProArt transduction. Murine hematopoietic cells transduced with AProArt exhibited no increase in replating potential in an *in vitro* immortalization assay, and analysis of AProArt lentivirus insertions showed no predilection for sites that could activate oncogenes. These efficacy and safety findings support institution of a clinical trial of gene addition therapy for ART-SCID.

Keywords: severe combined immunodeficiency, Artemis, gene therapy, lentivirus, radiation sensitivity

INTRODUCTION

SEVERE COMBINED IMMUNODEFICIENCY (SCID) is a group of genetic disorders characterized by markedly decreased circulating T cell numbers with impaired function plus absent or nonfunctional B cells.¹ About 20% of SCID patients lack both T and B cells, but have normal numbers of natural killer (NK) cells (T⁺B⁺NK⁺ SCID).² Mutations in genes

required for V(D)J rearrangement of the T and B cell antigen receptors cause T⁺B⁺NK⁺ SCID. These include lymphocyte specific recombinase activating genes 1 and 2 (*RAG1* and *RAG2*), as well as ubiquitously expressed *PRKDC*, encoding a DNA protein kinase c subunit, *LIG4*, encoding Ligase-4, a nonhomologous end-joining DNA repair component, and *DCLRE1C*, encoding Artemis. Because

*Correspondence: Dr. Jennifer M. Puck or Dr. Morton J. Cowan, Smith Cardiovascular Research Institute, University of California San Francisco, 555 Mission Bay Boulevard South, Rm SC-252K, San Francisco, CA 94158-9001. E-mail: jennifer.puck@ucsf.edu or mort.cowan@ucsf.edu

the latter three are required for repair of DNA double-strand breaks, defects in these genes also cause increased sensitivity to ionizing radiation and alkylating agents used as preparative regimens for hematopoietic cell transplantation (HCT).¹

Early diagnosis of SCID by newborn screening using the T cell receptor excision circle assay,²⁻⁴ followed by definitive treatment by allogeneic HCT, leads to excellent rates of survival, exceeding 90%.^{5,6} HCT from human leukocyte antigen (HLA)-identical siblings or unrelated donors results in the best outcomes, with 97% and 92% survival respectively.⁷ However, T-depleted, haploidentical HCT may require preparative chemotherapy to avoid rejection and achieve B cell reconstitution.^{6,8} Moreover, for recipients of HCT from donors other than HLA matched siblings, graft versus host disease (GVHD) can be a major complication with significant morbidity and mortality.⁶

The *DCLRE1C* gene encoding Artemis was first identified in patients with T⁺B⁺NK⁺ SCID (ART-SCID) who had increased cellular radiosensitivity.^{9,10} Artemis is an endonuclease essential for nonhomologous end-joining of DNA double-strand breaks that arise following exposure to external agents or during V(D)J recombination of T and B cell receptor genes.⁹ Navajo and Apache Native Americans from the southwestern United States have a frequent founder nonsense mutation in exon 8 of *DCLRE1C*, Y192X.^{11,12} Homozygosity for this mutation causes T⁺B⁺NK⁺ SCID in 1/2000 births, or 25 times the incidence of SCID in the general population.¹²⁻¹⁴

While HCT can cure ART-SCID, the heightened sensitivities to irradiation and alkylator chemotherapy conferred by *DCLRE1C* mutations are associated with increased early toxicity as well as late effects in survivors, including short stature, absent or malformed permanent dentition, and endocrinopathies.^{15,16} Thus, using gene addition to autologous hematopoietic stem cells (HSC) constitutes an alternative strategy for the treatment of ART-SCID to avoid the observed risks of partially matched or unrelated HSC allotransplant.¹⁷⁻¹⁹

We previously described a mouse model of ART-SCID (Art^{-/-}) that accurately represents both the T and B cell lymphopenia and the resistance to treatment by allogeneic mismatched HCT found in ART-SCID patients.^{20,21} Using this model, Multhap *et al.* demonstrated restoration of functional T and B lymphocytes by *ex vivo* complementation of the Artemis deficiency in murine stem cells using a vector carrying murine Artemis cDNA driven by the human Artemis promoter.²² Building upon these studies, we have now developed a novel lentiviral

vector with the human Artemis *DCLRE1C* cDNA under transcriptional regulation of its own human Artemis promoter, designated AProArt. We used AProArt to transduce human ART-SCID fibroblasts and CD34⁺ HSC as well as HSC from Art^{-/-} mice, achieving correction of radiation sensitivity in transduced human ART-SCID fibroblasts and successful *in vivo* and *in vitro* differentiation of transduced Artemis-deficient HSC into T and B cells.

METHODS

Animals

Mice were housed in sterile isolator cages and fed autoclaved chow, undergoing procedures according to approved protocols at the University of California, San Francisco. Art^{-/-} mice have been described previously,²⁰ and NSG mice were from the Jackson Laboratory (Bar Harbor, ME).

Lentivirus assembly, production and determination of titer

A 3750 bp DNA fragment was synthesized to include the *DCLRE1C* promoter (APro) from -1000 to the translational start site (NG_007276.1, NM_103385.2),²³ the 1024 bp human *DCLRE1C* coding sequence and 3' untranslated region, and a 590 bp woodchuck post-transcriptional regulatory element (WPRES). The putative protein-encoding sequence within the WPRES was modified to replace its translational start site (GCTGAcgtcctttccAtg) with a stop codon (ATCATcgtcctttccTtg) (modified bases in uppercase letters). The synthetic *MfeI*-*KpnI* fragment was cloned into lentiviral vector pCSI-CDF-CG-PRE²⁴ between *EcoRI* and *KpnI* to generate AProArt. A cytomegalovirus-green fluorescent protein (CMV-GFP) control vector with the same modified WPRES was generated by replacing the 5' end of pCS-AProArt through the *DCLRE1C* promoter and coding sequences with a *PvuI* - *XhoI* fragment isolated from pCSI-CDF-CG-PRE, generating pCS-CMV-GFP. The AProArt lentiviral vector was produced under good manufacturing practice conditions (Indiana University Vector Production Facility, Indianapolis, IN). Briefly, 293T cells were transfected with plasmids encoding AProArt provirus and vesicular stomatitis virus envelope G protein; lentiviral supernatant was harvested 48-72 hours after transfection and concentrated by ultracentrifugation. The control GFP lentivirus was produced in-house using the same protocol. Lentiviral titration in 293T cells was performed with serially diluted lentivirus; after 3 days the 293T cell DNA was isolated for vector-specific quantitative PCR (primer sequences available on request).

***In vitro* assays with human fibroblasts**

Immunoprecipitation and Western blotting. Skin fibroblasts from Artemis-deficient (ART-SCID) and Ligase-4 deficient patients and healthy controls were cultured in Dulbecco's modified Eagle medium with 10% fetal calf serum and antibiotics. Fibroblasts were incubated with GFP or AProArt lentivirus at multiplicity of infection 100 for 24 h. Protein was isolated 3 or 8 days post-transduction and precipitated using a rabbit anti-Artemis antibody (kindly provided by Steve Yannoni, Laurence Berkeley Laboratory, Berkeley, CA). For Western blot, a chicken polyclonal anti-Artemis antibody (Abcam) was used followed by a peroxidase-conjugated donkey anti-chicken second antibody (Gallus Immunotech) to detect precipitated protein.

Proliferation. Fibroblasts were exposed to 1, 3, or 5 Gy γ -radiation 3 days after lentivirus transduction. After 24 h, the cells were labeled with BrdU for 24 h, harvested, fixed, and stained with anti-BrdU antibody (BD Biosciences) following the manufacturer's instructions. Cell cycle distribution and BrdU incorporation were determined by flow cytometry using BD FACSVerser and analyzed using FlowJo software.

γ H2AX foci. Fibroblasts were seeded on chamber slides (Nunc Lab-Tek) and exposed to 4 Gy γ -radiation 3 days after transduction. After 6, 24, 48, and 168 h (7 days) the cells were fixed, permeabilized, blocked with 5% goat serum, and incubated with mouse anti- γ H2AX (Ser139) (Upstate Antibodies) and rabbit anti-53BP1 (Bethyl Laboratories) overnight at 4°C. The cells were washed, incubated with fluorochrome-conjugated secondary antibodies (Jackson ImmunoResearch) for 45 min at room temperature, washed thrice, stained with DAPI, mounted in Vectashield (Vector Laboratories) and analyzed using a fluorescence microscope (Keyence).

Isolation, transduction, and transplantation of murine bone marrow hematopoietic stem cells

Femurs, tibias, and fibulas from donor wild-type (WT) or Art^{-/-} CD45.1 mice were flushed and crushed to isolate bone marrow cells. After depleting lineage committed cells (mouse depletion kit, Miltenyi), cells were stained with c-kit and Sca-1 (clones 2B8 and D7, respectively, eBioscience) and lineage negative, Sca1 positive, c-kit positive (LSK) HSC were sorted (FACSJazz, BD Biosciences). LSK cells were plated in Retronectin-coated 96-well plates in X-Vivo-15 (Lonza) with L-glutamine

and murine cytokines: interleukin-3 (20 ng/mL, R&D Systems) and Flt3L, SCF, and TPO (100 ng/mL, R&D Systems) for 24 h. AProArt or GFP lentivirus was added at a final concentration of 5×10^7 IU/mL for 24 h at 37°C. One hundred thousand transduced Art^{-/-} HSC or 10^4 or 10^5 WT HSC were injected into Art^{-/-} CD45.2 recipient mice pretreated with 500 μ g of ultra-purified anti-mouse CD117 (anti-c-kit, ACK2, Biolegend) 9 days prior to transplant.

Functional assays with murine lymphocytes

T cell proliferation. Splenocytes from transplant recipients were isolated and resuspended in RPMI 1640 with 10% fetal bovine serum and antibiotics. One hundred thousand splenocytes per well in a 96-well plate were stimulated with 4 or 10 μ g/mL of Concanavalin-A (ConA, Sigma-Aldrich), 5 μ g/mL plate-bound anti-mouse CD3 ϵ (Tonbo), or medium only at 37°C for 4 days. Proliferation was measured by EdU incorporation (Click-iT EdU imaging kit, Life Technologies), following the manufacturer's instructions using a FACSVerser flow cytometer (BD Biosciences). The assays were carried out in triplicate.

Enzyme-linked immunosorbent assay for serum immunoglobulin M and immunoglobulin G antibody. ELISA using serum from transplanted mice injected intraperitoneally with 100 μ g of either NP₄₁-Ficoll or NP₂₄-keyhole limpet hemocyanin (KLH) (Biosearch Technologies, Novato, CA) was carried out as described.²⁰

Transduction and differentiation of human CD34⁺ HSC

With informed consent cytokine-mobilized peripheral blood stem cells (PBSC) were collected from an ART-SCID patient, under an internal review board-approved protocol (Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health), and CD34⁺ HSC were isolated (CliniMACS, Miltenyi Biotechnology). De-identified CD34⁺ cells from PBSC of healthy donors were used as control HSC.

Human HSC were prestimulated in retronectin-coated six-well plates ($1-2 \times 10^6$ cells/mL), in X-Vivo-15 (Lonza) with human SCF, Flt3L, thrombopoietin (Peprotech, all 100 ng/mL), IL-3 (Peprotech, 20 ng/mL), 1% human albumin, and gentamicin (50 μ g/mL) for 24 h. AProArt or GFP lentivirus was added at a final concentration of 1×10^8 IU/mL for 8 h at 37°C. The cells were then washed and cultured overnight in fresh medium, followed by a second transduction with fresh lentivirus for 8 h. Aliquots

were used for progenitor colony formation assays in semisolid medium with cytokines (Methocult, Stem Cell Technologies),²⁵ and 10^6 transduced cells were transplanted by intrahepatic injection into 150 cGy irradiated newborn to 3 day old NSG mice. The mice were bled every 4 weeks and sacrificed at 3 months of age for analysis of peripheral blood, bone marrow, and spleen for human cell chimerism by flow cytometry.

Determination of vector copy number and lentivirus integration site analysis

Lentiviral vector copy number for transduced murine LSK cells and human CD34⁺ cells was determined as described.^{25,26} The virus integration site assay was carried out as described.²⁷ Briefly, genomic DNA from lentivirus-transduced cells was digested and ligated with adaptors, and two rounds of nested PCR were performed. PCR products were cloned, analyzed by Sanger or next generation sequencing (HiSeq2500, Illumina), mapped to the human genome, and examined for oncogenic potential by Gene Ontology software.

In vitro immortalization assay

The *in vitro* immortalization (IVIM) assay was carried out as described.^{25,28} Briefly, prestimulated, lineage negative murine bone marrow cells were transduced with AProArt lentivirus; a long terminal repeats (LTR)-regulated γ -retroviral positive control (RSF91); or an intermediate positive control, a self-inactivating-lentivirus with an internal strong spleen focus-forming virus element. These gene-modified cells were expanded alongside a nontransduced negative control. After 14 days of expansion, the cultures were harvested and replated in 96-well plates with 100 cells/well. After 2 weeks, the wells were scored for immortalized clones. Differences in the incidence (Fisher's exact) and replating frequency (Mann-Whitney) were considered significant at $p < 0.05$.

RESULTS

Lentiviral vector design and production

Previous studies demonstrated that high-level Artemis protein expression was associated with DNA damage, increased apoptosis, and cell cycle arrest at G1.²⁹ The endogenous human *DCLRE1C* minimal 5' promoter (APro) was hypothesized to produce more moderate and physiologic expression of Artemis; reduced toxicity had been demonstrated in murine Artemis expression comparing APro versus the strong human elongation factor 1 alpha (EF1 α) promoter.³⁰ Building on this experi-

ence, human Artemis cDNA driven by its own endogenous promoter was cloned into self-inactivating lentiviral vector CSII with promoter and enhancer sequences deleted from the U3 region of the 3' LTR (Fig. 1).²⁴ The central polypurine tract was included to increase the virus titer and the frequency of integration into the host cell genome. This AProArt vector included a modified WPRE element to increase transgene expression in which the putative X protein start codon was mutated to a stop to reduce the risk of insertional mutagenesis. A control CMV-GFP vector was constructed with the same backbone (Fig. 1). The titer of each lentivirus was about 2×10^9 IU/mL.

Human Artemis expression and rescue from radiation toxicity in ART-deficient fibroblasts

To demonstrate Artemis protein expression and function following transduction with AProArt lentivirus, we transduced control (WT), Artemis-deficient (ART-SCID) and ligase-4 deficient (LIG4) human fibroblast cell lines with AProArt or control GFP lentiviruses. Like Artemis deficiency, ligase-4 deficiency results in radiation-sensitive SCID;^{31,32} therefore, LIG4 fibroblasts provided a control for specificity of the effects of AProArt transduction. At 3 days post transduction, Artemis protein was identified by Western blot in WT and LIG4 fibroblasts and in AProArt-transduced ART-SCID fibroblasts, but not in untreated or GFP-transduced ART-SCID fibroblasts (Fig. 2a). Similar expression was seen at 8 days (data not shown).

We also evaluated proliferation of the fibroblasts following exposure to 0–5 Gy of γ -irradiation (IR) (Fig. 2b). Without transduction, both the LIG4 deficient (middle panel) and untransduced ART-SCID (Fig. 2b, right panel) fibroblasts were radia-

Figure 1. Schematic representations of AProArt and control cytomagalovirus-green fluorescent protein (CMV-GFP) lentivirus vectors. The human Artemis (*DCLRE1C*) cDNA (Hu Artemis), with its endogenous promoter (APro) was introduced into self-inactivating lentiviral vector pCS with promoter and enhancer sequences deleted (X) from the U3 region of the 3' LTR to generate pCS-AProArt. A central polypurine tract (CPPT) was included in the vector backbone, preceded by the packaging site (Ψ). The vector includes a modified woodchuck post-transcriptional regulatory element (WPRE) and a 5' CMV promoter to generate full-length vector message for packaging. The control lentiviral vector with the same backbone, pCS-CMV-GFP, was constructed to express GFP under transcriptional regulation of the CMV promoter. LTR, long terminal repeats.

Figure 2. *In vitro* assays with human skin fibroblasts. **(a)** Immunoprecipitation Western blot to detect Artemis protein (upper arrow) in fibroblasts from control (wild type, WT), Artemis deficient (ART-SCID) or Ligase-4 deficient (LIG4) skin fibroblasts, untransduced (left) or transduced with GFP (middle) or AProArt lentivirus (right). **(b)** BrdU fibroblast proliferation with WT (left), LIG4 deficient (middle), or ART-SCID (right) cells, following exposure to ionizing radiation (IR). The fibroblasts were untransduced (broken line) or transduced with control (gray line) or AProArt lentivirus (black line). Mean $\pm$ standard deviation (SD), $n=3$ replicates; $*p < 0.05$. **(c)** Enumeration of γ H2AX foci indicating DNA double-strand breaks, in WT (left), LIG4 deficient (middle), or ART-SCID (right) fibroblasts, following exposure to 4 Gy IR. The fibroblasts were either untransduced (broken line) or transduced with AProArt (solid line). Mean $\pm$ SD, $n=3$ replicates; $*p < 0.05$; $**p < 0.001$.

tion sensitive, exhibiting up to 10-fold reduced proliferation compared to WT (Fig. 2b, left panel) following exposure to graded IR doses. The WT and LIG4 cells showed no change in proliferation when transduced with either control vector or AProArt; however, ART-SCID cells following AProArt transduction proliferated significantly more than untransduced or GFP-transduced ART-SCID cells ($p < 0.05$), achieving a level comparable to that of untransduced WT fibroblasts.

Finally, we evaluated γ H2AX foci as an indicator of ongoing repair of DNA damage; elevated numbers of foci persisting over time indicate incomplete DNA repair (Fig. 2c). AProArt transduction did not change the number of γ H2AX foci either at peak production (6 hours) or after 1 to 7 days in either the WT or the radiation sensitive LIG4 fibroblasts (Fig. 2c, left and middle panels); in contrast, DNA repair was normalized in AProArt-transduced ART-SCID fibroblasts (Fig. 2c, right panel). The numbers of γ H2AX foci in transduced ART-SCID cells were comparable to those of WT cells (Fig. 2c,

left panel), at all time points post IR. Thus AProArt lentivirus specifically reversed the DNA repair defect of Artemis-deficient human fibroblasts.

Determination of optimal AProArt lentivirus concentration for transduction of human CD34⁺ HSC

Previous studies suggested that overexpression of *DCLRE1C* could cause cellular cytotoxicity.²³ Moreover, *Art*^{-/-} murine HSC transduced with murine Artemis cDNA under transcriptional regulation of a strong EF1 α promoter failed to engraft in *Art*^{-/-} recipients.²² To determine the optimal concentration of AProArt lentivirus for transduction of human CD34⁺ HSC, we examined the relationship between lentivirus concentration, transduction rates and resulting vector copy number (VCN) per cell. Human mobilized PBSC from normal, Artemis-replete donors were transduced with increasing concentrations (1.25×10^7 to 2×10^8 IU/mL) of AProArt lentivirus and cultured for 14 days in either semi-solid medium for colony forming

assays or in liquid bulk cultures. With increasing AProArt lentivirus concentration, the proportion of transduced colonies increased, reaching approximately 50% at both 1×10^8 IU/mL and 4×10^8 IU/mL (Fig. 3a). With 1×10^8 IU/mL of AProArt lentivirus, an average VCN of 3 was achieved (Fig. 3b). Therefore, this concentration of lentivirus was selected for subsequent experiments.

Correction of immunodeficiency in Artemis-deficient mice

To determine whether human AProArt transduction could rescue the ability of $Art^{-/-}$ LSK HSC to differentiate into T and B lymphocytes, CD45.2 $Art^{-/-}$ mice pretreated with 500 μ g of anti-ckit antibody 9 days previously, to open marrow niches,³³ were injected with either 10^5 CD45.1 $Art^{-/-}$ LSK cells transduced with AProArt, or 10^4 or 10^5 untransduced CD45.1 WT LSK cells (Fig. 4a). As

Figure 3. Relationship between vector copy number or transduction efficiency, and lentivirus concentration. Healthy control human peripheral blood mobilized CD34⁺ cells transduced with increasing concentrations of AProArt lentivirus (black bars) were cultured for 14 days. (a) Percentage of lentivirus transduced colonies per total hematopoietic colonies isolated from semisolid medium, determined by quantitative PCR of individual colonies. Mean $\pm$ SD, $n=3$ replicates. (b) Average vector copy number per two copies of a human genomic control in cells grown in liquid bulk cultures, determined by quantitative PCR. Mean $\pm$ SD, $n=3$ replicates.

evidenced by the presence of donor-derived CD45.1 lymphocytes in their peripheral blood, five of six transplanted $Art^{-/-}$ mice engrafted with 10^5 AProArt-transduced $Art^{-/-}$ LSK HSC and all transplanted $Art^{-/-}$ mice engrafted with WT donor cells (Fig. 4a, black squares). Chimerism for T, B, and myeloid lineages in Table 1 indicated multilineage engraftment.

The post-transplant splenocytes were cultured in medium alone or with ConA (4 or 10 μ g/mL) or anti-mouse CD3 ϵ (5 μ g/mL), with proliferation of gated populations measured by flow cytometry 4 days later (Fig. 4b). Donor-derived CD45.1 T cells in $Art^{-/-}$ recipients of either WT (hatched bars) or AProArt-transduced $Art^{-/-}$ HSC (Fig. 4a, black bars) proliferated in response to stimuli. Analysis of absolute numbers of CD4⁺ and CD8⁺ T cells in the spleens showed that $Art^{-/-}$ mice transplanted with WT or AProArt-transduced $Art^{-/-}$ HSC had comparable numbers of CD4 helper and CD8 cytotoxic T cells, significantly more than those seen in $Art^{-/-}$ controls (Fig. 4c).

$Art^{-/-}$ mice transplanted with AProArt-transduced $Art^{-/-}$ HSC showed B cell development in the bone marrow, as did those receiving WT HSC, while untransplanted $Art^{-/-}$ mice had undetectable immature B cells (Fig. 4d). To assess specific antibody production *in vivo*, mice were immunized 16–24 weeks following transplant with 100 μ g of either NP₄₁-Ficoll or NP₂₄-KLH. Serum ELISA assays 42 days after immunization revealed that $Art^{-/-}$ mice transplanted with AProArt-transduced $Art^{-/-}$ HSC produced antigen-specific IgM and IgG in amounts comparable to those produced by $Art^{-/-}$ mice transplanted with WT HSC (Fig. 4e). Untransplanted $Art^{-/-}$ mice produced no immunoglobulin M or immunoglobulin G.

Colony forming assays with the AProArt-transduced $Art^{-/-}$ LSK HSC used for the above experiments showed a transduction efficiency of 87.5% and a mean vector copy number of 3 ± 2 per cell in positive colonies. The average VCN in the different lineages of the $Art^{-/-}$ mice transplanted with gene corrected cells was 3 ± 2 in T cells, 3 ± 1 in B cells, and 2 ± 2 in granulocytes.

Transduction and *in vivo* differentiation of human HSC

Cytokine-mobilized PBSC were obtained from an ART-SCID patient, homozygous for the Navajo founder mutation, who was 20 years post HCT and had partial T cell and no B cell reconstitution.³⁴ Isolated CD34⁺ HSC had no detectable cells of donor origin (data not shown). These ART-SCID HSC were transduced with 1×10^8 IU/mL AProArt or

Figure 4. Analysis of Art^{-/-} mice, transplanted with CD45.1 donor cells. **(a)** Percentage of donor-derived CD45.1 lymphocytes in peripheral blood at 4, 8, 12, 16, and 20 weeks post transplantation into Art^{-/-} CD45.2 recipients pretreated with 500 μ g of anti-c-kit antibody. Mice received 10⁵ CD45.1 AProArt-transduced Art^{-/-} (black squares, $n=5$), or 10⁴ (X's, $n=5$) or 10⁵ untransduced wild type (WT, gray circles, $n=3$) hematopoietic stem cells (HSC). Horizontal lines indicate mean chimerism. **(b)** Proliferation of CD3⁺ splenocytes from untransplanted control Art^{-/-} (clear bars, $n=5$); WT (gray bars, $n=7$); or Art^{-/-} mice transplanted with 10⁴ untransduced WT HSC (hatched bars, $n=4$) or AProArt lentivirus transduced Art^{-/-} HSC (black bars, $n=6$), measured as a percentage of EdU positive cells after 4 days in medium, 4 μ g/mL or 10 μ g/mL Concanavalin A (ConA), or 5 μ g/mL anti-mouse CD3 ϵ . Mean $\pm$ standard error of the mean (SEM), $n=3$ replicates; * $p<0.05$, ** $p<0.001$. **(c)** CD8⁺ (black bars) and CD4⁺ (gray bars) T cell numbers in control Art^{-/-} ($n=5$) and WT ($n=5$) mice, and Art^{-/-} mice transplanted with 10⁴ WT HSC ($n=7$) or AProArt lentivirus transduced Art^{-/-} HSC ($n=6$). Mean $\pm$ SEM; * $p<0.05$, ** $p<0.001$, compared to Art^{-/-} control. **(d)** B cell development in bone marrow of untransduced control Art^{-/-} (clear bars, $n=3$); WT (gray bars, $n=3$); and Art^{-/-} mice 3 months after transplant with 10⁴ WT HSC (hatched bars, $n=5$) or AProArt-transduced Art^{-/-} HSC (black bars, $n=5$). B cell progenitor subsets were: CD45⁺ B220⁺ CD43⁺ pro B cells; CD45⁺ B220⁺ CD43⁺ IgM⁻ pre B cells; and CD45⁺ B220⁺ CD43⁺ IgM⁺ immature B cells,¹⁷ as a percentage of CD45⁺ B220⁺ B cells. Mean $\pm$ SEM; * $p<0.05$. **(e)** Antigen-specific serum immunoglobulin (IgM and IgG) antibody responses to immunization with NP-KLH (minus pre-immune response) in WT (black diamonds, $n=3$) and Art^{-/-} (black squares, $n=3$) control mice, and Art^{-/-} recipients of Art^{-/-} HSC transduced with AProArt lentivirus (black triangles, $n=3$) or 10⁴ WT HSC (gray rectangles, $n=3$). Mean $\pm$ SD, $n=3$ replicates; * $p<0.05$ compared to Art^{-/-} controls. NP-KLH, NP24-keyhole limpet hemocyanin.

Table 1. *T, B, and myeloid chimerism (mean $\pm$ SD) in $Art^{-/-}$ CD45.2 recipients of CD45.1, AProArt transduced $Art^{-/-}$, or control untransduced lineage negative, Sca1 positive, c-kit positive hematopoietic stem cells*

Donor Cells	Weeks Post HCT	% Donor (CD45.1) ^a	% Donor Lymphocytes	% Donor CD3 ⁺ T Cells	% Donor B220 ⁺ B cells	% Donor Granulocytes
10 ⁵ $Art^{-/-}$ transduced with AProArt	12	19.47 $\pm$ 10.48	51.58 $\pm$ 8.32	36.57 $\pm$ 2.01	0.35 $\pm$ 0.53	6.37 $\pm$ 4.39
	16	26.56 $\pm$ 18.98	52.72 $\pm$ 21.31	37.85 $\pm$ 20.70	0.73 $\pm$ 0.46	8.77 $\pm$ 7.10
	20	36.08 $\pm$ 14.29	60.32 $\pm$ 17.34	45.28 $\pm$ 17.34	0.97 $\pm$ 0.70	11.83 $\pm$ 3.03
10 ⁴ WT untransduced	12	23.38 $\pm$ 7.83	56.94 $\pm$ 14.98	44.76 $\pm$ 12.51	3.02 $\pm$ 3.29	8.58 $\pm$ 4.54
	16	34.92 $\pm$ 11.03	70.72 $\pm$ 9.01	43.63 $\pm$ 8.67	3.11 $\pm$ 2.35	13.71 $\pm$ 7.67
	20	42.96 $\pm$ 13.11	71.82 $\pm$ 12.14	44.45 $\pm$ 10.84	3.49 $\pm$ 2.19	11.51 $\pm$ 9.45
10 ⁵ WT untransduced	12	34.43 $\pm$ 18.57	63.97 $\pm$ 14.9	58.35 $\pm$ 16.93	1.15 $\pm$ 0.79	16.35 $\pm$ 11.76
	16	42 $\pm$ 19.41	66.37 $\pm$ 17.35	61.66 $\pm$ 19.85	2.5 $\pm$ 2.05	12.91 $\pm$ 4.35
	20	50.43 $\pm$ 9.29	87.07 $\pm$ 4.60	81.58 $\pm$ 5.62	2.50 $\pm$ 1.74	17.87 $\pm$ 1.99

^aMean $\pm$ SD of at least five mice per group.

HCT, hematopoietic stem cell transplantation; WT, wild type (control).

GFP lentivirus and injected into irradiated, newborn to 3 day old NSG mice to assess whether transduction with AProArt would correct the *DCLRE1C* defect (Fig. 5). CD34⁺ HSC from healthy donors were similarly transduced with the control GFP virus and injected into irradiated recipients. At 4, 6, 8, and 10 weeks, peripheral blood was analyzed by flow cytometry for the appearance of human lymphocytes bearing the human pan-leukocyte marker CD45, and at 12 weeks bone marrow and spleens were harvested. NSG recipients of GFP-transduced control HSC, as well as those transplanted with AProArt-transduced ART-SCID HSC, exhibited sustained human lymphocyte chimerism (Fig. 5a). The average percent of human CD45 cells detected in the periphery of mice that received gene corrected cells from 8 weeks onwards, represented 27% of the cells detected in NSG mice transplanted with WT HSC, corresponding to the 25% transduction efficiency of the ART-SCID cells. GFP lentivirus-transduced ART-SCID HSC did not differentiate into mature lymphocytes, however, reflecting their uncorrected *DCLRE1C* defect. AProArt transduced ART-SCID CD34⁺ cells gave rise to differentiated human CD3⁺ T and CD19⁺ B cells, while GFP-transduced ART-SCID CD34⁺ cells failed to do so (Fig. 5b). Control CD34⁺ cells, whether transduced with AProArt or with GFP, differentiated into T and B cells in peripheral blood, bone marrow, and spleen of NSG mice.

DNA from the bone marrow of NSG recipient mice was used to confirm *de novo* polyclonal B cell development by assaying for Ig κ -receptor excision circles and rearranged linear mature gene coding joints (Kde CJ), by quantitative PCR (Fig. 5c).³⁵ Mice receiving GFP-transduced normal HSC or AProArt-transduced ART-SCID HSC had equivalent κ -receptor excision circles and coding joints, indicating that the human CD34⁺ cells had differentiated into mature Ig κ expressing B cells. In

contrast, mice receiving GFP-transduced ART-SCID CD34⁺ cells had no evidence of Ig κ rearrangement.

RNA from chimeric NSG mouse spleens was subjected to T cell receptor spectratyping to measure the diversity of human T cell receptor rearrangement (representative examples in Fig. 5d).³⁶ Again, mice with GFP-transduced normal or AProArt-transduced ART-SCID HSC showed several human recombinants yielding oligoclonal and polyclonal tracings within the 24 T cell receptor, V beta (TCR V β) families tested, while mice transplanted with GFP-transduced ART-SCID CD34⁺ cells had only minimal TCR V β rearrangement.

AProArt lentiviral vector copy number and integration site analysis

Colony forming assays with the AProArt-transduced ART-SCID HSC used for the above experiments showed a transduction efficiency of 25.4% and a mean vector copy number of 2 ± 1 per cell in positive colonies, confirming that human transduced HSC were within an acceptable integrant range for clinical application.

Lentivirus integration site analysis in bulk cultured AProArt or GFP transduced CD34⁺ cells from healthy donors showed a variety of insertion sites.²⁷ A total of 1,468 unique integration sites were recovered in AProArt-transduced samples, of which 924 (63%) were located within the promoter or genomic span of human reference gene sequences.³⁷ In GFP-transduced samples, a total of 1,529 unique integration sites were found, with 976 (64%) mapping to reference genes. To determine whether there were any preferred virus integration sites, the gene lists were examined using the DAVID Bioinformatics Resources 6.8,^{38,39} for gene ontology analysis. Following functional annotation (Biological Process Database, ≥ 3 -fold enrichment, Benjamini-Hochberg corrected *p* value <0.01), the gene list from the

Figure 5. Analysis of NSG mice transplanted with human CD34⁺ HSC. **(a)** Percent of human cells, identified by expression of human-specific pan-leukocyte marker CD45, detected in peripheral blood (PB), bone marrow (BM) or spleen, analyzed by flow cytometry at weeks (w) indicated post transplantation with GFP-transduced control (WT) HSC (clear bars, $n=6$), AProArt-transduced ART-SCID HSC (black bars, $n=7$) or GFP-transduced ART-SCID HSC (gray bars, $n=5$). Mean $\pm$ SD; $*p<0.05$. **(b)** Fraction of human CD19⁺ B cells (left panel) or CD3⁺ T cells (right panel) analyzed by flow cytometry, in total human CD45⁺ cells detected in the peripheral blood (PB), bone marrow (BM) and spleen of NSG mice transplanted with GFP-transduced control HSC (clear bars, $n=6$), AProArt-transduced ART-SCID HSC (black bars, $n=7$) or GFP-transduced ART-SCID HSC (gray bars, $n=5$). Mean $\pm$ SD; $*p<0.05$. **(c)** Quantification of human B cell Ig κ -chain rearrangement by quantitative PCR, identified as κ -chain restriction circles (KRECs) and Kde coding joints (Kde CJ), using DNA from NSG mice transplanted with GFP-transduced WT HSC (clear bars, $n=6$), AProArt-transduced ART-SCID HSC (black bars, $n=7$) or GFP-transduced ART-SCID HSC (gray bars, $n=5$). Mean $\pm$ SD; $*p<0.05$; $**p<0.001$. **(d)** T cell receptor diversity in 24 human V β T cell receptor (TCR) families by spectratyping, using RNA from spleens of NSG mice transplanted with GFP-transduced control HSC (left), AProArt lentivirus transduced ART-SCID HSC (middle) or GFP-transduced ART-SCID HSC (right). Monoclonal pattern, single peak per V β TCR family; oligoclonal, 1–4 peaks; polyclonal, ≥ 5 peaks. Color images available online at www.liebertpub.com/hum

AProArt-transduced samples showed slight enrichment in “chromatin modification” category (GO:0016568) (fold enrichment 3; corrected p value 1.5×10^{-4}), while the genes from GFP-transduced samples were overrepresented in “microtubule cytoskeleton organization” (GO:0000226) (fold enrichment 3; corrected p value 0.002) and “organelle localization” (GO:0051640) (fold enrichment 3.5; corrected p value 5.3×10^{-3}). No insertion sites in the T cell oncogene *LMO2* and no significant enrichment for genes with oncogenic potential were found among either AProArt or GFP insertion sites (data not shown, details available from the authors upon request).

Mutagenic potential of AProArt lentiviral vector

To assess the risk of insertional mutagenesis of the AProArt lentivirus, an IVIM assay was performed (Fig. 6). In this assay, nontransduced cells lack the ability to grow when very low seeding densities are used, while insertional mutants show a replating phenotype. The potential to induce immortalization is directly linked to the design of the integrating vectors.⁴⁰ RSF91, a gamma retroviral vector with intact LTRs, was used as a positive control to transduce murine lineage negative cells. From previous assays, it had been shown that

at VCN >3 and transduction efficiency >80% (Fig. 6, level Q₁), RSF91 showed a replating phenotype in 90% of the cases. Furthermore, 75% of these immortalized clones had a replating frequency > 3.17×10^{-4} . In the current assays, RSF91 scored positive seven of eight times, with a mean replating frequency of 1.61×10^{-3} . A second positive control lentiviral vector, with a spleen focus-forming virus promoter/enhancer element (Iv-SF), was able to immortalize cells in two out of three assays. In contrast, while cell growth was detected following transduction with the AProArt lentiviral vector, it was not distinguishable from background proliferation (mean replating frequency 4.67×10^{-7}). Therefore, the AProArt vector showed a significantly improved safety profile in the IVIM assay, with respect to both the incidence and replating frequency of the insertional mutants ($p < 0.01$).

DISCUSSION

A novel lentivirus, AProArt, expressing human *DCLRE1C* cDNA encoding Artemis under transcriptional control of the endogenous human *DCLRE1C* promoter, was constructed and evaluated for *ex vivo* correction of ART-SCID. Expression of AProArt complemented in a specific manner the radiation sensitivity of Artemis-deficient human skin fibroblasts. This vector, achieving a mean of one to

Figure 6. *In vitro* replating frequency to assess immortalization potential. Replating frequency of nontransduced mock cells ($n=3$), positive control samples, RSF91 ($n=8$) and Iv-SF ($n=3$), and the test vector AProArt ($n=9$). Bars, mean repopulating frequency; Q₁, lower detection range between background proliferation and the first quartile of the RSF91 clonal expectation value at viral copy number 3. Negative assay points manually inserted into the graph. * $p < 0.01$.

three copies per cell in transduced HSC, also restored T and B cell immunity in a murine *Art*^{-/-} model and enabled human ART-SCID CD34⁺ HSC to differentiate into mature T and B cells in NSG mice.

Although further study is required, AProArt integration site analysis to date revealed no predisposition for vector insertion into oncogene loci. Furthermore, no integration-mediated toxicity or transformation was observed in animals or in an *in vitro* insertional mutagenesis assay.

Children with SCID of all genotypes are susceptible to severe infections and typically do not survive beyond the first year of life without immune restoring treatment that has most often been allogeneic HCT, although enzyme replacement has been possible for adenosine deaminase deficiency (ADA) deficiency and gene addition therapy has been successful for ADA and X-linked common gamma chain deficiency.⁴¹⁻⁴³ For most patients with SCID, the only available treatment has been allogeneic HCT. The best outcomes occur with a matched sibling donor, because with such donors no conditioning with alkylating chemotherapy is necessary and the majority of patients reconstitute both T and B cell immunity.⁶ However, when a matched sibling is unavailable, as is the case for >80% of patients,¹⁵ and an alternative donor is used (i.e., a haplocompatible parent or a matched unrelated volunteer) without conditioning, rejection of the graft can occur, there is a significant risk of graft versus host disease (GVHD), only T cell immunity is typically restored and most patients require life-long gamma globulin therapy to replace B cell function. If chemotherapy with high dose alkylating agent is given as conditioning prior to HCT, T and B cell immunity are usually restored and gamma globulin therapy discontinued; however, this conditioning confers higher peritransplant risks in patients with infections, and the potential late effects of high dose alkylating agents in infants and young children with SCID have not been well characterized.^{6,43}

ART-SCID is the most difficult form of SCID to cure with HCT.^{32,34} In contrast to patients with other SCID genotypes, ART-SCID patients receiving a matched sibling HCT rarely achieve B cell reconstitution, and T cell immunity is often not fully reconstituted.^{15,36,43} When haplocompatible related donors are used without conditioning in ART-SCID, normal T cell immunity is even more difficult to achieve, no B cell reconstitution is seen, and there is an increased incidence of graft rejection that can be overcome only with high doses of immunosuppressing alkylating agents.^{15,32,34,36,43}

Graft resistance may in part be due to NK cell-mediated graft rejection, since NK cells are not deficient in ART-SCID.¹⁶ Use of unrelated allogeneic donors without conditioning in ART-SCID is associated with very poor B cell reconstitution and an increased risk of GVHD.⁷ Finally, because Artemis is essential for nonhomologous DNA double-strand break repair, patients with ART-SCID are highly sensitive to the high doses of alkylating agents required to overcome graft rejection and secure B cell reconstitution. They have poorer survival, increased infections, abnormal dental development, short stature, and increased endocrinopathies in comparison to children exposed to no or limited alkylators or children with SCID genotypes not associated with a global DNA repair defect, such as RAG-deficient SCID.^{15,34,43}

With the increasing adoption of newborn screening for SCID, affected children are being diagnosed in the neonatal period and treated before the onset of life-threatening infections with much improved outcomes compared to those identified and treated later with active infections.^{2,6} However, for young babies with ART-SCID lacking an HLA-matched sibling, the risks of toxicity from high dose alkylator preparative regimens to achieve B cell reconstitution and prevent rejection are even more profound. Thus, the use of autologous HSC corrected with gene therapy would be of great benefit, as it would eliminate the risk of GVHD and the need for high dose alkylators to overcome rejection.

Methods to open marrow niches without either alkylating agents or ionizing radiation are currently not available for clinical use. Elimination of HSC from marrow niches by anti-ckit antibody has shown promising results in the *RAG*^{-/-} mouse model³³ as well as our *Art*^{-/-} mouse model. The anti-human ckit antibody is undergoing evaluation in a clinical trial that has just been initiated and depending on results won't be available for gene therapy trials for several years. Currently, the only clinically available agent for opening marrow niches is busulfan. Both published⁶ and unpublished data from our own center suggest that very low exposures to busulfan (~25% of the marrow ablative exposure), can achieve T and B cell engraftment and reconstitution in patients with T⁻B⁻NK⁺ SCID. This is further supported by the experience with gene therapy for ADA SCID⁴¹ and X-linked SCID,⁴² in which very low doses of busulfan can achieve T and B cell immune reconstitution. Moreover, we have preliminary data (unpublished) to indicate that Artemis-deficient murine HSC are more susceptible to busulfan than wild type HSC,

which would suggest that even low dose exposure busulfan could be sufficient to be effective in a gene therapy clinical trial for ART-SCID. In the future, studies comparing low dose busulfan to anti- α -CD45 antibody may determine the optimal treatment for ART-SCID and other patients with SCID receiving hematopoietic cell therapy.

Adverse events from lentiviral gene transfer for ADA deficient and X-linked SCID have been mostly minimal to date,⁴⁴ in contrast to the insertional mutagenesis and leukemia that complicated the original X-linked SCID gene therapy mediated by gamma retrovirus vectors with intact LTR promoters.⁴⁵ Our use of a self-inactivating lentiviral vector with the autologous Artemis promoter should assure a low risk of insertional mutagenesis. Thus, risks of gene transfer for Artemis deficiency compare favorably with the known adverse consequences arising from the natural history of the disorder and from its standard treatment. The successful application of gene-corrected autologous HSC for children with ART-SCID may have a major positive impact on their survival and quality of life compared to what is currently achieved with allogeneic HCT.

Our results demonstrate the ability of the lentivirus vector AProArt to provide sufficient Artemis protein expression to correct radiation sensitivity and allow successful differentiation of hematopoietic stem cells to reconstitute T and B lymphoid lineages. Therefore we believe that gene therapy using this lentiviral vector can be clinically feasible as a treatment for human ART-SCID.

ACKNOWLEDGMENTS

These studies were supported by a research grant from the California Institute of Regenerative Medicine TR3-05535 and the National Institutes of Health National Institute of Allergy and Infectious Diseases, Division of Intramural Research and Warren Magnusen Clinical Center. We thank Steve Yannone, Laurence Berkeley Laboratory, for anti-Artemis antibody and Yanning Wang for technical expertise. We also thank the ART-SCID patients who volunteered to donate cells for these studies.

AUTHOR DISCLOSURE

No competing financial interests exist.

REFERENCES

1. Al-Herz W, Bousfiha A, Casanova JL, et al. Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. *Front Immunol* 2014; 5:162.
2. Kwan A, Abraham RS, Currier R, et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. *JAMA* 2014;312:729–738.
3. Brown L, Xu-Bayford J, Allwood Z, et al. Neonatal diagnosis of severe combined immunodeficiency leads to significantly improved survival outcome: the case for newborn screening. *Blood* 2011; 117:3243–3246.
4. Puck JM. Laboratory technology for population-based screening for severe combined immunodeficiency in neonates: the winner is T-cell receptor excision circles. *J Allergy Clin Immunol* 2012;129:607–616.
5. Dvorak CC, Cowan MJ, Logan BR, et al. The natural history of children with severe combined immunodeficiency: baseline features of the first fifty patients of the primary immune deficiency treatment consortium prospective study 6901. *J Clin Immunol* 2013;33:1156–1164.
6. Pai SY, Logan BR, Griffith LM, et al. Transplantation outcomes for severe combined immunodeficiency, 2000–2009. *N Engl J Med* 2014;371: 434–446.
7. Dvorak CC, Hassan A, Slatter MA, et al. Comparison of outcomes of hematopoietic stem cell transplantation without chemotherapy conditioning by using matched sibling and unrelated donors for treatment of severe combined immunodeficiency. *J Allergy Clin Immunol* 2014;134:935–943.e15.
8. Bertrand Y, Landais P, Friedrich W, et al. Influence of severe combined immunodeficiency phenotype on the outcome of HLA non-identical, T-cell-depleted bone marrow transplantation: a retrospective European survey from the European group for bone marrow transplantation and the European society for immunodeficiency. *J Pediatr* 1999;134:740–748.
9. Moshous D, Li L, Chasseval R, et al. A new gene involved in DNA double-strand break repair and V(D)J recombination is located on human chromosome 10p. *Hum Mol Gen* 2000;9:583–588.
10. Moshous D, Callebaut I, de Chasseval R, et al. Artemis, a novel DNA double-strand break repair/V(D)J recombination protein, is mutated in human severe combined immune deficiency. *Cell* 2001; 105:177–186.
11. Murphy S, Hayward A, Troup G, Devor EJ, Coons T. Gene enrichment in an American Indian population: an excess of severe combined immunodeficiency disease. *Lancet* 1980;2:502–505.
12. Li L, Drayna D, Hu D, et al. The gene for severe combined immunodeficiency disease in Athabaskan-speaking Native Americans is located on chromosome 10p. *Am J Hum Genet* 1998;62: 136–144.
13. Li L, Moshous D, Zhou Y, et al. A founder mutation in Artemis, an SNM1-like protein, causes SCID in Athabaskan-speaking Native Americans. *J Immunol* 2002;168:6323–6329.
14. Kwan A, Hu D, Song M, et al. Successful newborn screening for SCID in the Navajo Nation. *Clin Immunol* 2015;158:29–34.
15. O'Maricaigh AS, DeSantes K, Hu D, et al. Bone marrow transplantation for T-B- severe combined immunodeficiency disease in Athabaskan-speaking native Americans. *Bone Marrow Transplant* 2001; 27:703–709.
16. Dvorak CC, Cowan MJ. Radiosensitive severe combined immunodeficiency disease. *Immunology*

- and allergy clinics of North America 2010;30:125–142.
17. Mostoslavsky G, Fabian AJ, Rooney S, Alt FW, Mulligan RC. Complete correction of murine Artemis immunodeficiency by lentiviral vector-mediated gene transfer. *Proc Natl Acad Sci U S A* 2006;103:16406–16411.
 18. Benjelloun F, Garrigue A, Demerens-de Chappelandaine C, et al. Stable and functional lymphoid reconstitution in artemis-deficient mice following lentiviral artemis gene transfer into hematopoietic stem cells. *Mol Ther* 2008;16:1490–1499.
 19. Riviere J, Hauer J, Poirot L, et al. Variable correction of Artemis deficiency by I-Sce1-meganuclease-assisted homologous recombination in murine hematopoietic stem cells. *Gene Ther* 2014;21:529–532.
 20. Xiao Z, Dunn E, Singh K, Khan IS, Yannone SM, Cowan MJ. A non-leaky Artemis-deficient mouse that accurately models the human severe combined immune deficiency phenotype, including resistance to hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant* 2009;15:1–11.
 21. Li L, Salido E, Zhou Y, et al. Targeted disruption of the Artemis murine counterpart results in SCID and defective V(D)J recombination that is partially corrected with bone marrow transplantation. *J Immunol* 2005;174:2420–2428.
 22. Multhaup MM, Podetz-Pedersen KM, Karlen AD, et al. Role of transgene regulation in ex vivo lentiviral correction of artemis deficiency. *Hum Gene Ther* 2015;26:232–243.
 23. Multhaup M, Karlen AD, Swanson DL, et al. Cytotoxicity associated with artemis overexpression after lentiviral vector-mediated gene transfer. *Hum Gene Ther* 2010;21:865–875.
 24. Miyoshi H, Blomer U, Takahashi M, Gage FH, Verma IM. Development of a self-inactivating lentivirus vector. *J Virol* 1998;72:8150–8157.
 25. Carbonaro DA, Zhang L, Jin X, et al. Preclinical demonstration of lentiviral vector-mediated correction of immunological and metabolic abnormalities in models of adenosine deaminase deficiency. *Mol Ther* 2014;22:607–622.
 26. Charrier S, Ferrand M, Zerbato M, et al. Quantification of lentiviral vector copy numbers in individual hematopoietic colony-forming cells shows vector dose-dependent effects on the frequency and level of transduction. *Gene Ther* 2011;18:479–487.
 27. Zhang W, Muck-Hausl M, Wang J, et al. Integration profile and safety of an adenovirus hybrid-vector utilizing hyperactive sleeping beauty transposase for somatic integration. *PLoS One* 2013;8:e75344.
 28. Modlich U, Böhne J, Schmidt M, et al. Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity. *Blood* 2006;108:2545–53.
 29. Multhaup M, Karlen AD, Swanson DL, et al. Cytotoxicity associated with artemis overexpression after lentiviral vector-mediated gene transfer. *Hum Gene Ther* 2010;21:865–875.
 30. Multhaup MM, Gurram S, Podetz-Pedersen KM, et al. Characterization of the human artemis promoter by heterologous gene expression in vitro and in vivo. *DNA Cell Biol* 2011;30:751–761.
 31. O'Driscoll M, Cerosaletti KM, Girard PM, et al. DNA ligase IV mutations identified in patients exhibiting developmental delay and immunodeficiency. *Mol Cell* 2001;8:1175–1185.
 32. Cowan MJ, Gennery AR. Radiation-sensitive severe combined immunodeficiency: the arguments for and against conditioning before hematopoietic cell transplantation-what to do? *J Allergy Clin Immunol* 2015;136:1178–1185.
 33. Czechowicz A, Kraft D, Weissman IL, Bhattacharya D. Efficient transplantation via antibody-based clearance of hematopoietic stem cell niches. *Science* 2007;318:1296–1299.
 34. Schuetz C, Neven B, Dvorak CC, et al. SCID patients with ARTEMIS vs RAG deficiencies following HCT: increased risk of late toxicity in ARTEMIS-deficient SCID. *Blood* 2014;123:281–289.
 35. Sottini A, Ghidini C, Zanotti C, et al. Simultaneous quantification of recent thymic T-cell and bone marrow B-cell emigrants in patients with primary immunodeficiency undergone to stem cell transplantation. *Clin Immunol* 2010;136:217–227.
 36. Sarzotti M, Patel DD, Li X, et al. T cell repertoire development in humans with SCID after non-ablative allogeneic marrow transplantation. *J Immunol* 2003;170:2711–8.
 37. Rosenbloom KR, Armstrong J, Barber GP, et al. The UCSC Genome Browser database: 2015 update. *Nucleic Acids Res* 2015;43:D670–81.
 38. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat Protoc* 2009;4:44–57.
 39. Huang da W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. *Nucleic Acids Res* 2009;37:1–13.
 40. Zychlinski D, Schambach A, Modlich U, et al. Physiological promoters reduce the genotoxic risk of integrating gene vectors. *Mol Ther* 2008;16:718–725.
 41. Aiuti A, Cattaneo F, Galimberti S, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. *N Engl J Med* 2009;360:447–58.
 42. De Ravin SS, Wu X, Moir S, et al. Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency. *Sci Transl Med* 2016;8:335ra57.
 43. Neven B, Leroy S, Decaluwe H, et al. Long-term outcome after hematopoietic stem cell transplantation of a single-center cohort of 90 patients with severe combined immunodeficiency. *Blood* 2009;113:4114–24.
 44. Qasim W, Gaspar HB, Thrasher AJ. Progress and prospects: gene therapy for inherited immunodeficiencies. *Gene Ther* 2009;16:1285–1291.
 45. Howe SJ, Mansour MR, Schwarzwaelder K, et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. *J Clin Invest* 2008;118:3143–50.

Received for publication May 19, 2016;
accepted after revision August 31, 2016.

Published online: September 7, 2016.